{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:06:11Z","timestamp":1791237971292,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T00:00:00Z","timestamp":1713657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acne, a highly prevalent skin disease, can be particularly bothersome for patients of Asian background because of its impact on self\u2010confidence and social interactions. In addition to active acne lesions, some patients may develop sequelae such as scarring, macular\/postinflammatory hyperpigmentation, or erythema. The tendency of Asian skin to develop sequelae because of its increased susceptibility to irritation, cultural preferences for lighter skin phototypes, and differences in skincare regimens may all contribute to the increased burden of acne. Moreover, many Asia\u2010Pacific countries do not have their own guidelines for acne management, and those that do often have no schedule in place for regular updates. In this article, we provide a critical review of the published guidance for the management of acne and its sequelae in the Asia\u2010Pacific region, identifying gaps in current recommendations that could be addressed to enhance standards of acne care in Asia\u2010Pacific countries. Along with highlighting the importance of a comprehensive skincare regimen to increase treatment efficacy and adherence, we discuss topical retinoids and retinoid combination options in the acne armamentarium that may be beneficial for sequelae prevention and management, such as adapalene 0.3%\u2009\u00b1\u2009benzoyl peroxide 2.5%, tretinoin 0.05%, tazarotene 0.1%, and trifarotene 0.005%. In particular, trifarotene 0.005% has been observed to significantly reduce acne scar counts in a Phase 4 study. The recent data highlight the need to establish up\u2010to\u2010date guidance for acne and acne sequelae management in Asia\u2010Pacific countries to provide optimal care to Asian patients.<\/jats:p>","DOI":"10.1111\/ijd.17141","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T07:13:40Z","timestamp":1713683620000},"page":"704-713","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A review of the topical management of acne and its associated sequelae in the Asia\u2010Pacific region with a spotlight on trifarotene"],"prefix":"10.1111","volume":"63","author":[{"given":"Jo\u2010Ann","family":"See","sequence":"first","affiliation":[{"name":"Central Sydney Dermatology  Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-1563","authenticated-orcid":false,"given":"Rajeev","family":"Chavda","sequence":"additional","affiliation":[{"name":"Galderma SA  Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khen M.","family":"Kon","sequence":"additional","affiliation":[{"name":"Galderma ANZ  North Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg J.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Monash University  Clayton VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie S.","family":"Oblepias","sequence":"additional","affiliation":[{"name":"AcneCure Center  Para\u00f1aque Philippines"},{"name":"Medical Center Para\u00f1aque  Para\u00f1aque Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalina E.","family":"Nadela","sequence":"additional","affiliation":[{"name":"Fatima University Medical Center  Antipolo City Philippines"},{"name":"The Holistic Dermatology Clinic  Quezon City Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7607-3124","authenticated-orcid":false,"given":"Hazel H.","family":"Oon","sequence":"additional","affiliation":[{"name":"Division of Dermatology National Skin Centre  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Aurangabadkar","sequence":"additional","affiliation":[{"name":"Skin &amp; Laser Clinic  Hyderabad India"},{"name":"New Skin Clinic  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae H.","family":"Suh","sequence":"additional","affiliation":[{"name":"Seoul National University College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry H. L.","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine The University of Hong Kong  Hong Kong Special Administrative Region China"},{"name":"Wellman Center for Photomedicine Massachusetts General Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koushik","family":"Lahiri","sequence":"additional","affiliation":[{"name":"Apollo Multispeciality Hospitals  Kolkata India"},{"name":"Wizderm Speciality Skin and Hair Clinic  Kolkata India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,21]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13462"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19349"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2021.06.006"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133660"},{"key":"e_1_2_15_7_1","unstructured":"Galderma.Acne's hidden truth: burden of scarring summary report.https:\/\/hosted.bmj.com\/burden\/assets\/burden\u2010pdf\u2010scarring_1848.pdf. Accessed 4 Oct 2023."},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.2742"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13263"},{"key":"e_1_2_15_10_1","first-page":"24","article-title":"A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies","volume":"3","author":"Davis EC","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_15_11_1","first-page":"444","article-title":"Skin lightening and beauty in four Asian cultures","volume":"35","author":"Li EPH","year":"2008","journal-title":"Adv Consum Res"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2020.10.006"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/JDN.0000000000000129"},{"key":"e_1_2_15_14_1","first-page":"12","article-title":"Acne scarring\u2010pathogenesis, evaluation, and treatment options","volume":"10","author":"Connolly D","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-2077.104911"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.745822"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00633-4"},{"key":"e_1_2_15_18_1","first-page":"8223","article-title":"Post\u2010acne hyperpigmentation: evaluation of risk factors and the use of artificial neural network as a predictive classifier","volume":"13","author":"Al\u2010Qarqaz F","year":"2021","journal-title":"Dermatol Reports"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200910030-00002"},{"key":"e_1_2_15_20_1","unstructured":"Roche.Accutane (isotretioin) [package insert].U.S. Food and Drug Administration.2008.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/018662s059lbl.pdf. Accessed 2 November 2023."},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-2077.184043"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12993"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-2494.2006.00302.x"},{"key":"e_1_2_15_24_1","unstructured":"GRID\u2010Arendal.UV Index Worldmap.2009.https:\/\/www.grida.no\/resources\/7130. Accessed 16 October 2023."},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.01.019"},{"issue":"1","key":"e_1_2_15_26_1","first-page":"1","article-title":"Acne in India: guidelines for management \u2013 IAA consensus document","volume":"75","author":"Kubba R","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"e_1_2_15_27_1","first-page":"656","article-title":"Acne \u2010 best practice management","volume":"39","author":"Cook D","year":"2010","journal-title":"Aust Fam Physician"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2021.09.006"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2021.06.007"},{"key":"e_1_2_15_30_1","first-page":"34","article-title":"Acne management guidelines by the Dermatological Society of Singapore","volume":"12","author":"Oon HH","year":"2019","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2023.03.013"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00943-x"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2010.551109"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15519"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.02.053"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15584"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0231-8"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00454-6"},{"key":"e_1_2_15_39_1","unstructured":"TanghettiE BarnettP GallNL.Randomized comparison of tazarotene 0.1% cream and adapalene 0.3% gel in patients with at least moderate facial acne vulgaris and post inflammatory hyperpigmentation (PIH). Poster presented at MauiDerm 2010.\u00a0January 23\u201327 2010 Maui Hawaii.https:\/\/dermatologyandlasersurgery.com\/wp\u2010content\/uploads\/2020\/01\/2010\u2010104031\u2010TAZ\u2010Maui\u2010Poster\u2010final115.pdf. Accessed 9 November 2023."},{"key":"e_1_2_15_40_1","first-page":"237","article-title":"Trifarotene: a current review and perspectives in dermatology","volume":"9","author":"Cosio T","year":"2021","journal-title":"Biomedicine"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.7235"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.044"},{"key":"e_1_2_15_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15794"},{"key":"e_1_2_15_44_1","first-page":"E53","article-title":"A randomized, controlled trial of trifarotene plus doxycycline for severe acne vulgaris","volume":"15","author":"Del Rosso JQ","year":"2022","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_15_45_1","unstructured":"ClinicalTrials.gov.Search results for condition acne vulgaris treatment trifarotene cream study Phase 4 without results.https:\/\/clinicaltrials.gov\/search?cond=Acne%20Vulgaris&intr=Trifarotene%20Cream&aggFilters=phase:4 results:without. Accessed 13 December 2023."},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010023\u201001042\u20107"},{"key":"e_1_2_15_47_1","unstructured":"TanJ SeeJA DesaiS.New perspectives on personalized management of acne and acne sequelae. Presented at World Congress of Dermatology (WCD) 2023. July 3\u20138 2023 Singapore Singapore."},{"key":"e_1_2_15_48_1","unstructured":"SchleicherS MooreA RafalE Gagne\u2010HenleyA AblonG JohnsonS et\u00a0al.Evaluation of risk of formation of atrophic acne scars during acne treatment with trifarotene 50 \u03bcg\/g cream versus vehicle cream: results from a Phase 4 randomised double\u2010blind split\u2010face vehicle\u2010controlled clinical study (START). Poster P0127 presented at the European Academy of Dermatology and Venereology (EADV) 2023. October 11\u201314 2023 Berlin Germany."},{"key":"e_1_2_15_49_1","unstructured":"AlexisA CesljarevicE BrowningJ Del RossoJQ CalatayudA DhawanS et\u00a0al.Efficacy and safety of trifarotene cream 50 \u03bcg\/g for the treatment of acne\u2010induced post\u2010inflammatory hyperpigmentation in subjects with Fitzpatrick Skin Types I\u2013VI: results from a Phase IV trial (LEAP). Poster P0131 presented\u00a0at the European Academy of Dermatology and Venereology (EADV) 2023. October 11\u201314 2023 Berlin Germany."},{"key":"e_1_2_15_50_1","unstructured":"PiccardiN Grivet\u2010SeyveM LachmannN ChavdaR.A tailored skincare routine provides benefits to patients with moderate acne vulgaris and post\u2010inflammatory hyperpigmentation in combination with topical trifarotene. Poster P0027 presented at the European Academy of Dermatology and Venereology (EADV) 2023. October 11\u201314 2023 Berlin Germany."},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.017"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T17:38:18Z","timestamp":1716572298000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.17141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,21]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/ijd.17141"],"URL":"https:\/\/doi.org\/10.1111\/ijd.17141","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,21]]},"assertion":[{"value":"2023-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}